Birinyi Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.69M Buy
1,460
+359
+33% +$424K 0.4% 30
2026
Q2
$1.32M Sell
1,101
-90
-8% -$92K 0.31% 34
2026
Q1
$1.1M Buy
1,191
+136
+13% +$138K 0.3% 35
2025
Q4
$1.13M Hold
1,055
– – 0.28% 33
2025
Q3
$805K Hold
1,055
– – 0.21% 41
2025
Q2
$822K Hold
1,055
– – 0.24% 38
2025
Q1
$871K Hold
1,055
– – 0.28% 36
2024
Q4
$814K Sell
1,055
-3,953
-79% -$3.27M 0.22% 38
2024
Q3
$4.44M Buy
5,008
+228
+5% +$205K 1.27% 17
2024
Q2
$4.33M Buy
4,780
+2,105
+79% +$1.68M 1.3% 18
2024
Q1
$2.08M Buy
2,675
+1,046
+64% +$744K 0.68% 24
2023
Q4
$950K Buy
1,629
+879
+117% +$513K 0.34% 36
2023
Q3
$403K Hold
750
– – 0.16% 45
2023
Q2
$352K Sell
750
-950
-56% -$398K 0.13% 51
2023
Q1
$584K Buy
+1,700
New +$573K 0.24% 46
2022
Q4
– Sell
-1,550
Closed -$501K – 58
2022
Q3
$501K Buy
+1,550
New +$491K 0.23% 43
2021
Q4
– Sell
-900
Closed -$208K – 66
2021
Q3
$208K Buy
+900
New +$222K 0.07% 66
2019
Q4
– Sell
-4,000
Closed -$447K – 78
2019
Q3
$447K Sell
4,000
-100
-2% -$11.1K 0.19% 55
2019
Q2
$454K Buy
+4,100
New +$483K 0.19% 55

Other funds holding LLY

Birinyi Associates's LLY Position: Q3 2026 in Review

Birinyi Associates increased its Eli Lilly (LLY) stake by 33% in Q3 2026, buying an estimated $424K and bringing the position to 1,460 shares worth $1.69M. The position accounts for 0.4% of the portfolio, ranked #30.

Birinyi Associates first reported a position in LLY in Q2 2019 and has held it in 19 quarters since. The position peaked at $4.44M in Q3 2024. 2,091 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Birinyi Associates held 1,460 shares of Eli Lilly worth $1.69M as of Q3 2026.
  • Birinyi Associates bought 359 Eli Lilly shares in Q3 2026, an estimated $424K.
  • Eli Lilly made up 0.4% of Birinyi Associates's portfolio in Q3 2026, its #30 holding.
  • Birinyi Associates first reported a position in Eli Lilly in Q2 2019 and has held it in 19 quarters since.
  • Birinyi Associates's Eli Lilly position peaked at $4.44M in Q3 2024.
  • 2,091 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Birinyi Associates's 13F filing for Q3 2026, filed 28 Oct 2026.